Form D · Hedge Fund
Verdad Biotech Fund, L.P.
Boston, MA · CIK 0002139106
Offering snapshot reported Jun 9, 2026 · SEC filing
- Reported sold
- $8.1M Indefinite offering
- Investors reported
- 9 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Apr 1, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jun 9, 2026 | Initial | $8,099,001 | No comparison | 9 | SEC filing |
Offering details
- Securities
- Pooled investment fund
- Exemptions
- 06b, 3C, 3C.7
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-586685
None, although the general partner of the issuer receives investment management fees and a special profit allocation.
Source: Form D, filed Jun 9, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Dan Rasmussen | Executive |
| N/A Vclf Gp, L.P. | Executive |
| N/A Verdad Asset Management | Executive |
Issuer details
Industry: Pooled Investment Fund (See others in industry)
Address:
695 Atlantic Ave. 4 Th Floor
Boston, MA, 02111
Boston, MA, 02111